BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 32578483)

  • 41. B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide: selecting the optimal heart failure marker in patients with impaired kidney function.
    Jafri L; Kashif W; Tai J; Siddiqui I; Azam I; Shahzad H; Ghani F
    BMC Nephrol; 2013 May; 14():117. PubMed ID: 23725445
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure.
    Lok DJ; Klip IT; Lok SI; Bruggink-André de la Porte PW; Badings E; van Wijngaarden J; Voors AA; de Boer RA; van Veldhuisen DJ; van der Meer P
    Am J Cardiol; 2013 Sep; 112(6):831-7. PubMed ID: 23820571
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Not Available].
    Protasov VN; Narusov OY; Skvortsov AA; Protasova DE; Kuznetsova TV; Petrukhina AA; Masenko VP; Tereshchenko SN
    Kardiologiia; 2019 Jan; 59(1S):53-64. PubMed ID: 30706839
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect Modification of Chronic Kidney Disease on the Association of Circulating and Imaging Cardiac Biomarkers With Outcomes.
    Gregg LP; Adams-Huet B; Li X; Colbert G; Jain N; de Lemos JA; Hedayati SS
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28679558
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Associations Between Cardiac Biomarkers and Cardiac Structure and Function in CKD.
    Stein NR; Zelnick LR; Anderson AH; Christenson RH; deFilippi CR; Deo R; Go AS; He J; Ky B; Lash JP; Seliger SL; Soliman EZ; Shlipak MG; Bansal N;
    Kidney Int Rep; 2020 Jul; 5(7):1052-1060. PubMed ID: 32647762
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiac and kidney markers for cardiovascular prediction in individuals with chronic kidney disease: the Atherosclerosis Risk in Communities study.
    Matsushita K; Sang Y; Ballew SH; Astor BC; Hoogeveen RC; Solomon SD; Ballantyne CM; Woodward M; Coresh J
    Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1770-7. PubMed ID: 24876355
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Longitudinal increases in blood biomarkers of inflammation or cardiovascular disease and the incidence of venous thromboembolism.
    Folsom AR; Lutsey PL; Heckbert SR; Poudel K; Basu S; Hoogeveen RC; Cushman M; Ballantyne CM
    J Thromb Haemost; 2018 Oct; 16(10):1964-1972. PubMed ID: 30007116
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
    Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Natriuretic and Inflammatory Biomarkers as Risk Predictors of Heart Failure in Middle-Aged Men From the General Population: A 21-Year Follow-Up.
    Ergatoudes C; Thunström E; Hansson PO; Morales D; Mandalenakis Z; Rosengren A; Zhong Y; Caidahl K; Fu M
    J Card Fail; 2018 Sep; 24(9):594-600. PubMed ID: 30048772
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multimarker Analysis of Serially Measured GDF-15, NT-proBNP, ST2, GAL-3, cTnI, Creatinine, and Prognosis in Acute Heart Failure.
    Gürgöze MT; van Vark LC; Baart SJ; Kardys I; Akkerhuis KM; Manintveld OC; Postmus D; Hillege HL; Lesman-Leegte I; Asselbergs FW; Brunner-la-Rocca HP; van den Bos EJ; Orsel JG; de Ridder SPJ; Pinto YM; Boersma E
    Circ Heart Fail; 2023 Jan; 16(1):e009526. PubMed ID: 36408685
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multi-variable biomarker approach in identifying incident heart failure in chronic kidney disease: results from the Chronic Renal Insufficiency Cohort study.
    Janus SE; Hajjari J; Chami T; Mously H; Badhwar AK; Karnib M; Carneiro H; Rahman M; Al-Kindi SG
    Eur J Heart Fail; 2022 Jun; 24(6):988-995. PubMed ID: 35587997
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study.
    Sharma A; Stevens SR; Lucas J; Fiuzat M; Adams KF; Whellan DJ; Donahue MP; Kitzman DW; Piña IL; Zannad F; Kraus WE; O'Connor CM; Felker GM
    JACC Heart Fail; 2017 Oct; 5(10):724-734. PubMed ID: 28958347
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure.
    Pascual-Figal DA; Manzano-Fernández S; Boronat M; Casas T; Garrido IP; Bonaque JC; Pastor-Perez F; Valdés M; Januzzi JL
    Eur J Heart Fail; 2011 Jul; 13(7):718-25. PubMed ID: 21551163
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event.
    Pareek M; Bhatt DL; Vaduganathan M; Biering-Sørensen T; Qamar A; Diederichsen AC; Møller JE; Hindersson P; Leósdóttir M; Magnusson M; Nilsson PM; Olsen MH
    Eur J Prev Cardiol; 2017 Oct; 24(15):1648-1659. PubMed ID: 28644092
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Growth differentiation factor-15 combined with N-terminal prohormone of brain natriuretic peptide increase 1-year prognosis prediction value for patients with acute heart failure: a prospective cohort study.
    Hao J; Cheang I; Zhang L; Wang K; Wang HM; Wu QY; Zhou YL; Zhou F; Xu DJ; Zhang HF; Yao WM; Li XL
    Chin Med J (Engl); 2019 Oct; 132(19):2278-2285. PubMed ID: 31567379
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction.
    Khan SQ; Ng K; Dhillon O; Kelly D; Quinn P; Squire IB; Davies JE; Ng LL
    Eur Heart J; 2009 May; 30(9):1057-65. PubMed ID: 19168526
    [TBL] [Abstract][Full Text] [Related]  

  • 57. N-terminal pro-B-type natriuretic peptide, left ventricular mass, and incident heart failure: Multi-Ethnic Study of Atherosclerosis.
    Choi EY; Bahrami H; Wu CO; Greenland P; Cushman M; Daniels LB; Almeida AL; Yoneyama K; Opdahl A; Jain A; Criqui MH; Siscovick D; Darwin C; Maisel A; Bluemke DA; Lima JA
    Circ Heart Fail; 2012 Nov; 5(6):727-34. PubMed ID: 23032197
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum N-terminal Pro-brain Natriuretic Peptide Level is Associated with the Development of Chronic Kidney Diseases in Patients with Type 2 Diabetes.
    Sawada R; Hashimoto Y; Senmaru T; Tanaka M; Ushigome E; Yamazaki M; Fukui M
    Endocr Metab Immune Disord Drug Targets; 2018; 18(6):590-595. PubMed ID: 29697035
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Panel of emerging cardiac biomarkers contributes for prognosis rather than diagnosis in chronic heart failure.
    Jungbauer CG; Riedlinger J; Block D; Stadler S; Birner C; Buesing M; König W; Riegger G; Maier L; Luchner A
    Biomark Med; 2014; 8(6):777-89. PubMed ID: 25224934
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changes in Natriuretic Peptide Levels and Subsequent Kidney Function Decline in SPRINT.
    Ascher SB; Berry JD; Katz R; de Lemos JA; Bansal N; Garimella PS; Hallan SI; Wettersten N; Jotwani VK; Killeen AA; Ix JH; Shlipak MG
    Am J Kidney Dis; 2024 May; 83(5):615-623.e1. PubMed ID: 37992982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.